Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.34 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19993990 | 1.00 | FFAR3 (0.37) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27130887 | 1.00 | FFAR3 (0.37) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Sulfuric Acid SCHEMBL28848153 | 0.98 | FFAR3 (0.36) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL10957419 | 0.95 | FFAR3 (0.33) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butane SCHEMBL3658803 | 0.92 | FFAR3 (0.46) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL362989 | 0.85 | TSHR (0.38) | — | |
| Biphenyl SCHEMBL3682453 | 0.84 | LMNA (0.33) | — | |
| SCHEMBL18130775 | 0.84 | — | — | |
| SCHEMBL2521502 | 0.83 | TSHR (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL11776045 | 0.83 | TSHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009120-A1 | Ocular Compositions and Methods Thereof | UNIVERSITY OF MISSISSIPPI MEDICAL CENTER | 2024-01-11 | — | — | US | claimed |
| EP-4288026-A1 | COMPOSITIONS COMPRISING A MULTI-TAIL SURFACTANT AND A CATIONIC POLYMER AND USES | SPECIALTY OPERATIONS FRANCE (FR) | 2023-12-13 | — | — | EP | claimed |
| WO-2022167672-A1 | COMPOSITIONS COMPRISING A MULTI-TAIL SURFACTANT AND A CATIONIC POLYMER AND USES | RHODIA OPERATIONS (FR) | 2022-08-11 | — | — | WO | claimed |
| WO-2022150032-A1 | SURFACTANT COMPOSITIONS WITH SUPRAMOLECULAR STRUCTURES FOR INDUSTRIAL, HOUSEHOLD, AGRICULTURAL AND OIL/GAS USE | BPS JUST ENERGY TECHNOLOGY, LLC (US) | 2022-07-14 | — | — | WO | claimed |
| EP-2794212-A1 | PROCESS FOR THE MANUFACTURE OF A MESOPOROUS PRODUCT | Saint-Gobain Centre de Recherches et d'Etudes Européen (FR) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093853-A1 | PROCESS FOR THE MANUFACTURE OF A MESOPOROUS PRODUCT | SAINT-GOBAIN CENTRE DE RECHERCHES ET D'ETUDES EUROPEEN (FR) | 2013-06-27 | — | — | WO | claimed |
| WO-2009100441-A2 | DEPOT FORMULATIONS | IMPAX LABORATORIES, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| EP-1153051-A1 | PROCESS FOR THE PREPARATION OF ANIONIC AQUEOUS POLYMER DISPERSIONS CONTAINING NO VOLATILE TERTIARY AMINE, OBTAINED DISPERSION AND COATING RESULTING FROM SAID DISPERSION | STAHL INTERNATIONAL B.V. (NL) | 2001-11-14 | — | — | EP | claimed |
| WO-2001027178-A1 | PROCESS FOR THE PREPARATION OF ANIONIC AQUEOUS POLYMER DISPERSIONS CONTAINING NO VOLATILE TERTIARY AMINE, OBTAINED DISPERSION AND COATING RESULTING FROM SAID DISPERSION | STAHL INTERNATIONAL B.V. (NL) | 2001-04-19 | — | — | WO | claimed |
| EP-0009543-A1 | Nested hollow fiber humidifier | Jackson, Richard R., Dr. (US) | 1980-04-16 | — | — | EP | claimed |
| US-3951877-A | Heavy-duty granular detergent composition with sodium citrate builder | LION FAT & OIL CO., LTD. (JA) | 1976-04-20 | — | — | US | claimed |
| US-12622950-B2 | Treatment of patients with severe von Willebrand disease undergoing elective surgery by administration of recombinant VWF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12569435-B2 | Ocular compositions and methods thereof | UNIVERSITY OF MISSISSIPPI MEDICAL CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4637958-A1 | HIGH PERFORMANCE FILTER MEDIA | Hollingsworth & Vose Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4583858-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| US-4249699-A | FROM MINERAL MATTER | OTISCA INDUSTRIES, LTD. (US) | 1981-02-10 | — | — | US | disclosed |
| US-4244988-A | Method of coating linear polyester with aqueous latex | CIBA-GEIGY AG (CH) | 1981-01-13 | — | — | US | disclosed |
| EP-0009543-A1 | Nested hollow fiber humidifier | Jackson, Richard R., Dr. (US) | 1980-04-16 | — | — | EP | disclosed |
| EP-0008213-A1 | The use of synthetic polymeric compositions as wallpaper adhesive | Ciba Specialty Chemicals Water Treatments Limited (GB) | 1980-02-20 | — | — | EP | disclosed |
| US-4160726-A | Ultrafiltration process for the concentration of polymeric latices | ABCOR, INC. (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569435-B2 | Ocular compositions and methods thereof | FLT1, VEGFA, AREG | CA1 4858/4885CA4 4722/4885FFAR3 4513/4885 |
| US-12622950-B2 | Treatment of patients with severe von Willebrand disease undergoing elective surgery by administration of recombinant VWF | F5, F8, F2 | CA1 4681/4885CA4 4830/4885FFAR3 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.